144 related articles for article (PubMed ID: 24863682)
81. A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Nomura M; Kii T; Kawada J; Hirota M; Ohta T; Matsuyama J; Sakai D; Shimokawa T; Kurokawa Y; Kawakami H; Tsujinaka T; Satoh T
Esophagus; 2022 Oct; 19(4):711-716. PubMed ID: 35723843
[TBL] [Abstract][Full Text] [Related]
82. [Pathologic response and changes of serum VEGF during chemoradiotherapy may predict prognosis in non-surgical patients with esophageal carcinoma].
Wang J; Yu JP; Wang JL; Ni XC; Sun ZQ; Sun W; Nie B; Jiang JT; Sun SP; Wu CP
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):589-95. PubMed ID: 27531478
[TBL] [Abstract][Full Text] [Related]
83. Sustained complete remission with taxane-based chemotherapy in stage IVB primary vaginal squamous cell carcinoma.
Aggarwal S; Goel G; Banerji N; Khullar H
Hematol Oncol Stem Cell Ther; 2009; 2(2):362-3. PubMed ID: 20118062
[No Abstract] [Full Text] [Related]
84. [Docetaxel with concurrent radiotherapy in patients with inoperable or relapsed oesophageal cancer].
Kubo N; Morimoto J; Sakurai K; Tanaka H; Muguruma K; Amano R; Noda E; Nagahara H; Takashima T; Yashiro M; Yamada N; Onoda N; Maeda K; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2261-3. PubMed ID: 21224541
[TBL] [Abstract][Full Text] [Related]
85. CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer.
Karadag I; Karakaya S; Ates O; Cakmak Oksuzoglu OB
J Coll Physicians Surg Pak; 2021 Mar; 31(3):326-329. PubMed ID: 33775025
[TBL] [Abstract][Full Text] [Related]
86. [A Case of Advanced Esophagogastric Junction Cancer Responding to Combined Modality Therapy].
Shinohara H; Haruki S; Ohata Y; Ueda H; Arita K; Ito K; Matsumoto A; Takiguchi N
Gan To Kagaku Ryoho; 2020 Mar; 47(3):466-468. PubMed ID: 32381917
[TBL] [Abstract][Full Text] [Related]
87. Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer.
Takada A; Nakamura T; Takayama K; Makita C; Suzuki M; Azami Y; Kato T; Tsukiyama I; Hareyama M; Kikuchi Y; Daimon T; Toyomasu Y; Ii N; Nomoto Y; Sakuma H; Fuwa N
Cancer Med; 2016 Mar; 5(3):506-15. PubMed ID: 26806272
[TBL] [Abstract][Full Text] [Related]
88. Trimodality therapy for esophageal cancer at high volume facilities is associated with improved postoperative outcomes and overall survival.
Haque W; Verma V; Butler EB; Teh BS
Dis Esophagus; 2019 Apr; 32(4):. PubMed ID: 30052835
[TBL] [Abstract][Full Text] [Related]
89. Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience.
Fujisawa Y; Nakamura Y; Kawachi Y; Otsuka F
J Dermatolog Treat; 2014 Oct; 25(5):419-23. PubMed ID: 23210914
[TBL] [Abstract][Full Text] [Related]
90. [Combined modality treatment of oesophageal cancer].
Stahl M; Ruhstaller T
Internist (Berl); 2014 Jan; 55(1):7-8, 10-4. PubMed ID: 24154497
[TBL] [Abstract][Full Text] [Related]
91. Combined modality therapy for esophageal cancer.
Gamliel Z; Krasna MJ
Curr Oncol Rep; 1999; 1(2):149-54. PubMed ID: 11122812
[TBL] [Abstract][Full Text] [Related]
92. Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy.
Fujita K; Motoyama S; Sato Y; Wakita A; Nagaki Y; Minamiya Y; Miura M
Esophagus; 2022 Jan; 19(1):146-152. PubMed ID: 34347217
[TBL] [Abstract][Full Text] [Related]
93. Current developments in the management of locally advanced esophageal cancer.
McNamara MJ; Adelstein DJ
Curr Oncol Rep; 2012 Aug; 14(4):342-9. PubMed ID: 22544559
[TBL] [Abstract][Full Text] [Related]
94. Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
Werner HM; Trovik J; Halle MK; Wik E; Akslen LA; Birkeland E; Bredholt T; Tangen IL; Krakstad C; Salvesen HB
PLoS One; 2014; 9(2):e90141. PubMed ID: 24587245
[TBL] [Abstract][Full Text] [Related]
95. A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma.
Sun X; Han S; Gu F; Lin G; Wang Z; Wang Y; Xu Y
J Cancer; 2016; 7(9):1066-73. PubMed ID: 27326249
[TBL] [Abstract][Full Text] [Related]
96. Targeted taxane therapy for cancer.
Whelan J
Drug Discov Today; 2002 Jan; 7(2):90-2. PubMed ID: 11790612
[No Abstract] [Full Text] [Related]
97. Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?
Abraham AG; Joseph K; Spratlin JL; Zebak S; Alba V; Iafolla M; Ghosh S; Abdelaziz Z; Lui A; Paulson K; Bedard E; Chua N; Tankel K; Koski S; Scarfe A; Severin D; Zhu X; King K; Easaw JC; Mulder KE
Clin Oncol (R Coll Radiol); 2022 Sep; 34(9):e369-e376. PubMed ID: 35680509
[TBL] [Abstract][Full Text] [Related]
98. Does chemotherapy regimen matter in the neoadjuvant treatment of esophageal cancer?
Logarajah S; Jeyarajah P; Darwish M; Moslim M; Jureller M; Osman H; Jeyarajah DR
J Gastrointest Oncol; 2022 Dec; 13(6):2713-2720. PubMed ID: 36636066
[TBL] [Abstract][Full Text] [Related]
99. Real-World Experience of Patient's Compliance and Clinical Outcomes for Trimodality Treatment for Esophageal Cancer: a Study from a Cancer Center in North-East India.
Das G; Arun PS; Roy PS; Sarma G; Nath J; Kalita DJ; Talukdar A
Indian J Surg Oncol; 2024 Jun; 15(2):241-249. PubMed ID: 38741641
[TBL] [Abstract][Full Text] [Related]
100. Predicting toxicity of platinum and taxane-based chemotherapy in older patients with gynecologic cancer.
Yoshida H; Shintani D; Kawashima N; Fujiwara K
J BUON; 2020; 25(2):736-742. PubMed ID: 32521861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
